ABT
ABBOTT LABORATORIES
Next earnings Jul 15, 2026 (before open) · consensus $1.29 EPS, $12.7B rev
Last earnings -6.0% on 2026-04-16
$95.40
▲ +2.90%$95.40▼ -27.56%
over 1Y
L $82.56H $134.49
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.9%
1W+2.3%
1M+9.7%
3M-6.7%
YTD-22.3%
1Y-27.6%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 34 analysts
Buy
High-quality med-tech compounder: devices and margins are surging while the scary -51% EPS is just a 2024 comp distortion.
Operating income $8.05B · FY2025
The read
The fundamentals carry the rating, but the price is rich (~67% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
The headline looks ugly — net income and diluted EPS both fell 51.3% (EPS $3.72) — but that is a comparison artifact, not deterioration. FY2024 net income of $13.4B was nearly double Abbott's $5.72B–$7.07B range across 2021–2023, so the cleaner read of underlying performance is operating income up 18.0% to $8.05B on revenue of $44.3B (+5.7%). The MD&A confirms quality is improving across the P&L: operating margin expanded to 18.2% from 16.3% (2024) and 16.2% (2023), and gross margin rose to 52.6% from 50.9%, driven by margin-improvement initiatives despite tariff and FX headwinds. Revenue is back above its 2021–2022 level after the 2023 COVID-driven dip.
The engine is Medical Devices, which grew 11.9% ex-FX in 2025 at a 33.7% segment operating margin, led by Diabetes Care CGM sales of $7.6B (up from $6.4B) and a deep approval pipeline (Volt PFA, Tendyne TMVR, TriClip in Japan, expanded Navitor TAVI). This is a durable, structurally growing franchise. The offsets are well understood and largely transitory: Diagnostics fell 4.5% ex-FX as COVID testing rolled off to $297M (from $1.6B in 2023) and China volume-based procurement pressured pricing, dragging the segment margin to 19.5% from 24.4%; Nutrition was flat.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 19, 2026, 2:16 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Is ABT a buy? The one-page verdict, explained →
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Gross profit | — | — | — | — | — |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B |
| Net income | $7.07B | $6.93B | $5.72B | $13.4B | $6.52B |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Net margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$171B
EV / EBITDA—
EV / Sales3.8
EV / FCF23.1
P / FCF22.5
PEG (trailing)—
Earnings yield3.9%
FCF yield4.5%
Quality & risk
ROIC (est.)9.8%
Free cash flow$7.39B
Total debt$12.9B
Net cash-$4.41B
Piotroski F-Score4/8
Capital returns
Buyback yield0.5%
Dividend yield (est.)2.5%
Shareholder yield3.0%
Shares Δ YoY+0.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 10-Q Quarterly report2026-04-29
Q1 FY26: med devices/CGM drive growth; Exact Sciences acquisition pending
- 8-K Officer / director change2026-04-27
Annual meeting: voting results, board/officer changes and bylaw amendments
- 8-K Other event2026-04-17
Other-event disclosure (8.01); no material change to fundamentals signaled
- 8-K Earnings results2026-04-16
Released Q1 2026 results; medical-device-led growth continues
- 8-K Other event2026-03-23
Other-event disclosure (8.01); routine corporate matter
- DEF 14A Proxy statement2026-03-13
Annual proxy: board slate, executive pay and shareholder voting items
- 8-K Material agreement2026-03-09
New debt/credit agreement, likely funding the $23B Exact Sciences deal
- 8-K Material agreement2026-02-26
Entered a material definitive agreement (likely acquisition-financing related)
- 10-K Annual report2026-02-20
FY25 rev +5.7%, op margin 18.2%; net income -51% vs 2024 one-time gain; $23B M&A
Recent filings
all on EDGAR ↗4Period ending 2026-06-302026-07-01open ↗4Period ending 2026-06-302026-07-01open ↗4Period ending 2026-06-302026-07-01open ↗4Period ending 2026-06-302026-07-01open ↗4Period ending 2026-06-302026-07-01open ↗4Period ending 2026-06-302026-07-01open ↗4Period ending 2026-06-272026-06-29open ↗4Period ending 2026-05-072026-06-18open ↗11-KPeriod ending 2025-12-312026-06-18open ↗SDFiling2026-05-27open ↗144Filing2026-05-15open ↗4Period ending 2026-04-282026-04-29open ↗
Frequently asked
- Is ABBOTT LABORATORIES (ABT) a buy?
- ABT currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. High-quality med-tech compounder: devices and margins are surging while the scary -51% EPS is just a 2024 comp distortion.
- What is ABT's fair value?
- A Modified-Graham model based on ABT's SEC fundamentals estimates a fair value of about $31.62. It is an estimate from reported earnings, not a price target.
- Is ABT overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, ABT currently appears overvalued relative to its SEC-grounded earnings power.
- What is ABBOTT LABORATORIES's quality score?
- ABT scores 62.71494863041569/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000001800, latest 10-Q filed 2026-04-29) · EODHD · Proprietary analysis · as of 6/19/2026, 6:16:04 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.